Skip to content
  • About
    • CEO Comment
    • Story of Nanologica
    • Management team
    • Board of Directors
    • Career
    • Media Library
    • Privacy policy
  • Chromatography
    • NLAB Saga® for Preparative Chromatography
    • SVEA® HPLC Columns
    • Catalogues / Brochures
    • Applications
    • Technical Support
  • Investor relations (EN)
    • Press releases
    • Financial reports
    • Presentations
    • Calendar
    • Corporate Governance
    • The Share
    • Subscribe
  • Investor relations (SE)
    • Pressmeddelanden
    • Finansiella rapporter
    • Presentationer
    • Kalender
    • Bolagsstyrning
    • Aktien
    • Prenumerera
  • Latest news
  • Contact
  • About
    • CEO Comment
    • Story of Nanologica
    • Management team
    • Board of Directors
    • Career
    • Media Library
    • Privacy policy
  • Chromatography
    • NLAB Saga® for Preparative Chromatography
    • SVEA® HPLC Columns
    • Catalogues / Brochures
    • Applications
    • Technical Support
  • Investor relations (EN)
    • Press releases
    • Financial reports
    • Presentations
    • Calendar
    • Corporate Governance
    • The Share
    • Subscribe
  • Investor relations (SE)
    • Pressmeddelanden
    • Finansiella rapporter
    • Presentationer
    • Kalender
    • Bolagsstyrning
    • Aktien
    • Prenumerera
  • Latest news
  • Contact

Investment Case

Read more:

  • Press releases
  • Financial reports
  • Presentations
  • Calendar
  • Corporate Governance
    • Corporate Governance Reports
    • Articles of Association
    • General Meetings
    • Nomination Committee
    • Board of Directors
    • Board of Directors work
    • Management team
    • Remuneration
    • Incentive programs
    • Auditors
    • Whistleblowing
  • The Share
    • Investment Case
    • Ownership structure
    • Analysts and analyses
    • Share capital development
    • Rights Issues
    • Listing on Nasdaq Stockholm
    • Subscribe
  • Media Library
  • Subscribe
  • Home
  • Press releases
  • Financial reports
  • Presentations
  • Calendar
  • Corporate Governance
    • Corporate Governance Reports
    • Articles of Association
    • General Meetings
    • Nomination Committee
    • Board of Directors
    • Board of Directors work
    • Management team
    • Remuneration
    • Incentive programs
    • Auditors
    • Whistleblowing
  • The Share
    • Investment Case
    • Ownership structure
    • Analysts and analyses
    • Share capital development
    • Rights Issues
    • Listing on Nasdaq Stockholm
    • Subscribe
  • Media Library
  • Subscribe
  • Home

Investment case

5 reasons to invest in Nanologica

By developing chromatography products that enable pharmaceutical manufacturers to streamline production and lower their production costs, Nanologica not only strives to create value for its shareholders, but also to contribute to more patients having access to adequate treatments.

Nanologica AB (publ)
Forskargatan 20 G
SE-151 36 Södertälje
Sweden

Email: info@nanologica.com
Tel: +46 (0)8 410 749 49

Subscribe

To subscribe to our press releases and financial reports, please enter your e-mail address. Tick the box to approve the subscription and accept our privacy policy:

About us

Nanologica is a Swedish life science tools company that develops, manufactures, and sells advanced consumables to pharmaceutical manufacturers. Nanologica’s products are specially developed for the purification of peptide drugs, such as insulin and GLP-1 analogues. Due to effective purification and a long lifetime for the products, they can increase productivity and reduce costs for pharmaceutical manufacturers. Nanologica operates in a global niche market that is growing as a result of increased demand for drugs for the treatment of diabetes and obesity. The company’s mission is to increase access to cost-effective drugs through its purification products and thereby contribute to more patients around the world having access to life-saving treatments. The company is headquartered in Södertälje and Nanologica’s share (NICA) is listed for trading on Nasdaq Stockholm Main Market.

© Nanologica 2025
This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Cookie settingsACCEPT
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT